<DOC>
	<DOCNO>NCT01395316</DOCNO>
	<brief_summary>The MRI study design identify possible mechanism alemtuzumab act protect brain inflammation may enhance repair remyelination .</brief_summary>
	<brief_title>Alemtuzumab Surrogate Markers Disease Activity Repair Using Advanced MRI Measures Subjects With Relapsing Remitting Multiple Sclerosis</brief_title>
	<detailed_description>To identify specific change T cell subset function Relapsing Remitting Multiple Sclerosis .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Inclusion Criteria 1 . Signed , informed consent form ( ICF ) 2 . Age 18 50 year old ( inclusive ) sign ICF 3 . Diagnosis MS per update McDonald criterion , cranial MRI scan demonstrate white matter lesion attributable MS within 10 year screen 4 . Onset MS symptom ( determined neurologist ) within 15 year screen 5 . EDSS score 0.0 5.0 ( inclusive ) 6 . &gt; =2 MS attack ( first episode relapse ) occur 24 month prior screen , &gt; =1 attack 12 month prior screen , objective neurological sign confirm physician 7 . Subjects previously enrol randomized interferon beta 1a CAREMS 323 324 study , treat Alemtuzumab CAREMS extension study eligible participate immunology MRI study protocol . Exclusion Criteria 1 . Received prior therapy MS corticosteroid within 28 day screen ; e.g. , interferon , IV immunoglobulin , glatiramer acetate 2 . Exposure natalizumab within 6 month screen 3 . Any prior exposure mitoxantrone , mycophenolate mofetil , azathioprine , cladribine , cyclophosphamide , cyclosporine A , methotrexate , rituximab , immunosuppressive agent systemic corticosteroid treatment 4 . Has progressive form MS 5 . History malignancy ( exception basal cell skin carcinoma ) 6 . Previous hypersensitivity reaction immunoglobulin product 7 . Intolerance pulse corticosteroid , especially history steroid psychosis 8 . CD4+ , CD8+ , CD19+ ( i.e. , absolute CD3+CD4+ , CD3+CD8+ , CD19+/mm3 ) count &lt; LLN Screening ; abnormal cell count ( ) return within normal limit , eligibility may reassess 9 . Seropositivity human immunodeficiency virus ( HIV ) 10 . Significant autoimmune disease ( e.g , immune cytopenia , rheumatoid arthritis , systemic lupus erythematosus , connective tissue disorder ; vasculitis ; inflammatory bowel disease ; severe psoriasis ) 11 . Presence antithyroid stimulate hormone ( TSH ) receptor ( TSHR ) antibodies 12 . Active infection , e.g , deeptissue infection , Investigator consider sufficiently serious preclude study participation 13 . Latent tuberculosis unless effective antituberculosis therapy complete , active tuberculosis . Patients assess risk base screen questionnaire . 14 . Infection hepatitis B virus hepatitis C virus 15 . Of childbearing potential positive serum pregnancy test 16 . Unwilling agree use reliable acceptable contraceptive method throughout study period 17 . Major psychiatric disorder adequately control treatment 18 . Epileptic seizure adequately control treatment 19 . Major systemic disease illness would , opinion Investigator , compromise patient safety interfere interpretation study result 20 . Medical , psychiatric , cognitive , condition , Investigator 's opinion , compromise patient 's ability understand patient information , give informed consent , comply trial protocol , complete study 21 . Confirmed platelet count &lt; low limit normal ( LLN ) evaluate laboratory Screening document &lt; 100,000/uL within past year sample without clump 22 . Prior history invasive fungal infection 23 . Cervical high risk human papillomavirus ( HPV ) positivity abnormal cervical cytology abnormal squamous cell undetermined significance ( ASCUS ) . The patient may eligible condition effectively treat ( eg , followup HPV test negative cervical abnormality treat ) . 24 . Seropositive Trypanosoma cruzi Human Tlymphotropic virus type I type II ( HTLVI/II ) ( test require endemic region ) 25 . Any illness infection ( latent active ) , Investigator 's opinion , could exacerbate alemtuzumab treatment 26 . Any hepatic renal function value grade 2 high Screening , exception hyperbilirubinemia due Gilbert 's syndrome . See Table , draw National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events v3.0 ( CTCAE ) , publish 09 August 2006</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>